Monopar Therapeutics Reports $3.9 Million Net Loss in Q1 2026, Increases R&D Spending

Monopar Therapeutics Inc. reported a net loss of $3.9 million for the first quarter of 2026, compared to a loss of $2.6 million in the same period of the previous year. The company's total operating expenses increased to $5.2 million, up from $3.2 million year-over-year, primarily driven by a significant rise in research and development (R&D) costs, which reached $3.5 million, compared to $1.6 million in the prior year. This increase is attributed to higher contractor and consulting expenses, as well as increased personnel costs related to R&D activities. General and administrative expenses also rose to $1.7 million from $1.6 million, reflecting increased personnel costs and other administrative expenses.

As of March 31, 2026, Monopar's cash, cash equivalents, and investments totaled approximately $137.5 million, a decrease from $140.7 million at the end of 2025. The company’s accumulated deficit stood at $93.4 million, and it has not yet generated any revenue from product sales. Monopar anticipates that its current funds will be sufficient to support operations through at least December 31, 2027, as it continues to develop its product candidates, including ALXN1840 for Wilson disease and various radiopharmaceutical programs.

In terms of strategic developments, Monopar has focused on advancing its clinical pipeline, particularly the ALXN1840 program, which it licensed from Alexion Pharmaceuticals in October 2024. The company is preparing to submit a New Drug Application (NDA) for ALXN1840, which has shown promise in clinical trials for treating Wilson disease. Additionally, Monopar is conducting Phase 1 clinical trials for its radiopharmaceutical candidates, MNPR-101-Zr and MNPR-101-Lu, which target advanced cancers. The company has also entered into a long-term supply agreement with NorthStar Medical Radioisotopes for actinium-225, a key component in its radiopharmaceutical development.

Operationally, Monopar has made significant progress in its clinical trials, with ongoing studies for both ALXN1840 and its radiopharmaceuticals. The company is actively enrolling patients in its trials and has reported positive early data regarding the efficacy of its imaging agent, MNPR-101-Zr. The company’s workforce has also expanded, reflecting its commitment to advancing its clinical programs and preparing for potential commercialization. Monopar's management remains focused on securing additional funding through various means, including equity offerings and strategic partnerships, to support its ongoing development efforts and operational needs.